Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.By Accumetrics Inc., PRNE
Tuesday, March 1, 2011
VerifyNow System to be used in Drug Developer's Clinical Studies
SAN DIEGO, March 2, 2011 - Accumetrics, Inc., a privately-held developer and marketer of the
VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic
system for measuring platelet reactivity to multiple antiplatelet agents,
announced today that the company has signed an agreement with Portola
Pharmaceuticals, Inc. to develop and supply the VerifyNow System and
VerifyNowTests for use in clinical trials.
The VerifyNow System is widely used by practicing physicians to assess
patients' platelet response to various antiplatelet therapies already
available on the market, such as aspirin, P2Y12 inhibitors (e.g. Plavix(R)
and Effient(R)) and GP IIb/IIIa inhibitors. The VerifyNow System is also a
frequently used tool of clinical researchers to measure the antiplatelet
effect of drugs in development. By incorporating the VerifyNow System in
pharmaceutical clinical trials, data are generated to support the integration
of platelet reactivity testing in the patient care pathway as new agents are
introduced to the market.
"With the signing of this agreement, Accumetrics is solidifying its role
as a premier partner of pharmaceutical companies in the development and
validation of new and emerging antiplatelet drugs," said Timothy I. Still,
President and CEO of Accumetrics. "With the trend towards individualized and
targeted approaches to treating patients, the VerifyNow System plays an
important role at both the commercial and development ends of the spectrum."
The VerifyNow System is widely used in various clinical settings where
antiplatelet medications are prescribed to reduce the occurrence of future
thrombotic events such as heart attack and stroke.
Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry-leading and widely accessible diagnostic
tests for rapid platelet function assessment.
Accumetrics' VerifyNow System is the first rapid and easy-to-use platform
to help physicians determine an individual's response to multiple
antiplatelet agents. Addressing every major antiplatelet drug, including
FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient)
and clopidogrel (Plavix)), and GP IIb/IIIa inhibitors (e.g. ReoPro(R) and
Integrilin(R)), the VerifyNow System provides a valuable tool to help
physicians make informed treatment decisions. For more information about the
Company and its products, visit www.accumetrics.com.
The Accumetrics logo and VerifyNow are registered trademarks of
Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc.
Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is
a registered trademark of sanofi-aventis. Effient is a registered trademark
of Eli Lilly and Company.
CONTACT: Megan Rusnack Lippert/Heilshorn & Associates +1-212-838-3777 email@example.com Timothy I. Still President and CEO Accumetrics +1-858-404-8260 firstname.lastname@example.org
Megan Rusnack of Lippert/Heilshorn & Associates, +1-212-838-3777, mrusnack at lhai.com, for Accumetrics; or Timothy I. Still, President and CEO of Accumetrics, +1-858-404-8260, press at accumetrics.com
Tags: Accumetrics Inc., california, March 2, San diego